IRON CHELATION AND VITAMIN-D3 IN COMBINATION WITH AZACITIDINE IMPROVES TREATMENT RESPONSE IN 19 HIGH RISK MYELODYSPLASTIC SYNDROMES AFTER AZACITIDINE FAILURE

被引：0
|
作者：
Brechemier, D. [1 ]
Comont, T. [1 ]
Bertoli, S. [2 ]
Dutertre, M. [1 ]
Recher, C. [2 ]
Adoue, D. [1 ]
Beyne-Rauzy, O. [1 ]
机构：
[1] Inst Univ Canc Toulouse Oncopole, Internal Med, Toulouse, France
[2] Inst Univ Canc Toulouse Oncopole, Hematol, Toulouse, France
来源：
LEUKEMIA RESEARCH | 2015年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
91
引用
收藏
页码：S46 / S46
页数：1
相关论文
共 50 条
  • [21] Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromes
    Garcia, Jacqueline S.
    Platzbecker, Uwe
    Odenike, Olatoyosi
    Fleming, Shaun
    Fong, Chun Yew
    Borate, Uma
    Jacoby, Meagan A.
    Nowak, Daniel
    Baer, Maria R.
    Peterlin, Pierre
    Chyla, Brenda
    Wang, Huipei
    Ku, Grace
    Hoffman, David
    Potluri, Jalaja
    Garcia-Manero, Guillermo
    BLOOD, 2025, 145 (11) : 1126 - 1135
  • [22] The Effects of Continued Azacitidine (AZA) Treatment Cycles on Response in Higher-Risk Patients (Pts) with Myelodysplastic Syndromes (MDS)
    Silverman, Lewis R.
    Fenaux, Pierre
    Mufti, Ghulam J.
    Santini, Valeria
    Hellstrom-Lindberg, Eva
    Gattermann, Norbert
    Sanz, Guillermo
    List, Alan F.
    Gore, Steven D.
    Seymour, John F.
    Backstrom, Jay
    McKenzie, David
    Beach, C. L.
    BLOOD, 2008, 112 (11) : 91 - 91
  • [23] 5-AZACITIDINE TREATMENT RESTORES RESPONSE TO EPOETIN THERAPY IN HIGH RISK MYELODYSPLASTIC (MDS) PATIENTS
    Volpe, M.
    Volpe, A.
    HAEMATOLOGICA, 2012, 97 : 588 - 589
  • [24] Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes
    Borthakur, Gautam
    Huang, Xuelin
    Kantarjian, Hagop
    Faderl, Stefan
    Ravandi, Farhad
    Ferrajoli, Alessandra
    Torma, Ritva
    Morris, Gail
    Berry, Donald
    Issa, Jean-Pierre
    LEUKEMIA & LYMPHOMA, 2010, 51 (01) : 73 - 78
  • [25] Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia
    Voso, Maria Teresa
    Breccia, Massimo
    Lunghi, Monia
    Poloni, Antonella
    Niscola, Pasquale
    Finelli, Carlo
    Bari, Alessia
    Musto, Pellegrino
    Zambello, Renato
    Fianchi, Luana
    Alimena, Giuliana
    Leone, Giuseppe
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2013, 90 (04) : 345 - 348
  • [26] Outcome of Patients with Lower-Risk Myelodysplastic Syndrome (MDS) After Azacitidine (AZA) Treatment Failure.
    Mishra, Asmita
    Lancet, Jeffrey E.
    Al Ali, Najla H.
    Padron, Eric
    Ho, Viet Q.
    Little, Bryan J.
    Pinilla-Ibarz, Javier
    List, Alan F.
    Komrokji, Rami S.
    BLOOD, 2012, 120 (21)
  • [27] TREATMENT OF PATIENTS WITH HIGH-RISK MYELODYSPLASTIC SYNDROMES RECEIVING AZACITIDINE WHO ARE ENROLLED IN AVIDA, A LONGITUDINAL PATIENT REGISTRY
    Grinblatt, L.
    Narang, X.
    Malone, M.
    Sweet, A.
    Dunne, S.
    Sullivan, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 531 - 531
  • [28] PI-PLCbeta1 expression in patients with high-risk Myelodysplastic syndromes is affected by azacitidine treatment.
    Finelli, Carlo
    Follo, Matilde Y.
    Bosi, Costanza
    Mongiorgi, Sara
    Clissa, Cristina
    Martinelli, Giovanni
    Baccarani, Michele
    Martelli, Alberto M.
    Cocco, Lucio
    BLOOD, 2007, 110 (11) : 722A - 722A
  • [29] Treatment With Decitabine (DAC) After Azacitidine (AZA) Failure In High Risk Myelodysplastic Syndrome (MDS) and Advanced Chronic Myelomonocytic Leukemia (CMML)
    Braun, Thorsten
    Cherait, Amina
    Berthon, Celine
    Willekens, Christophe
    Park, Sophie
    Rigal, Marthe
    Brechignac, Sabine
    Harel, Stephanie
    Thepot, Sylvain
    Quesnel, Bruno
    Gardin, Claude
    Ades, Lionel
    Fenaux, Pierre
    BLOOD, 2013, 122 (21)
  • [30] CLINICAL RESPONSE TO THE ASSOCIATION OF AZACITIDINE AND LENALIDOMIDE IN HIGH-RISK MYELODYSPLASTIC SYNDROMES. A RANDOMIZED PHASE II MULTICENTER STUDY
    Finelli, C.
    Clissa, C.
    Follo, M. Y.
    Stanzani, M.
    Parisi, S.
    Avanzini, P.
    Bosi, C.
    Castagnari, B.
    Candoni, A.
    Crugnola, M.
    Giannini, M. B.
    Gobbi, M.
    Leonardi, G.
    Rigolin, G. M.
    Russo, D.
    Tosi, P.
    Visani, G.
    Cocco, L.
    Cavo, M.
    LEUKEMIA RESEARCH, 2015, 39 : S50 - S50
12345